Regdanvimab in patients with mild-to-moderate SARS-CoV-2 infection: A propensity score-matched retrospective cohort study.
Lee S, Lee SO, Lee JE, Kim KH, Lee SH, Hwang S, Kim SW, Chang HH, Kim Y, Bae S, Kim AS, Kwon KT.
Lee S, et al. Among authors: kim as, kim sw, kim y, kim kh.
Int Immunopharmacol. 2022 May;106:108570. doi: 10.1016/j.intimp.2022.108570. Epub 2022 Feb 4.
Int Immunopharmacol. 2022.
PMID: 35168079
Free PMC article.